A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out

Vivos Inc.
(OTCQB: RDGL)

Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)
Home
About Us
FAQ's
PRnT™
IsoPet®
RadioGel®
The Peltier Chiller
The History of Vivos Inc.
IDE Submission
Press Releases
Monthly Reports
SEC Filings
Research Papers
Contact Us
Subscribe

Vivos Inc.
(OTCQB: RDGL)

Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)
Home
About Us
FAQ's
PRnT™
IsoPet®
RadioGel®
The Peltier Chiller
The History of Vivos Inc.
IDE Submission
Press Releases
Monthly Reports
SEC Filings
Research Papers
Contact Us
Subscribe
More
  • Home
  • About Us
  • FAQ's
  • PRnT™
  • IsoPet®
  • RadioGel®
  • The Peltier Chiller
  • The History of Vivos Inc.
  • IDE Submission
  • Press Releases
  • Monthly Reports
  • SEC Filings
  • Research Papers
  • Contact Us
  • Subscribe
  • Home
  • About Us
  • FAQ's
  • PRnT™
  • IsoPet®
  • RadioGel®
  • The Peltier Chiller
  • The History of Vivos Inc.
  • IDE Submission
  • Press Releases
  • Monthly Reports
  • SEC Filings
  • Research Papers
  • Contact Us
  • Subscribe

Vivos Inc.

Our Mission

Develop and deploy Precision Radionuclide Therapy™ worldwide to treat humans and animals.

Our Values

  • Caring  - We wish to present a superb therapy option to people and animals suffering from cancer.
  • Integrity - Honest communication to all parties. Communicate results that have been implemented, not promises to increase stock price.
  • Innovation - To continuously improve our cancer treatment and the production process by developing alternate particles such as GammaGel™ and AlphaGel™.
  • Distributed leadership - Authorize our talented team members to excel within their sphere of expertise and influence.
  • Risk identification - Anticipate any objectives to avoid future issues. These include strengthening our intellectual property, certifying alternate production contractors and refining techniques for future indication for use such as caudal heel pain in equines, deep tissue injections and coating cavities. 
  • Teamwork - Continue to work together with the common goal in mind - to bring a new generation cancer therapy, Precision Radionuclide Therapy™ to the world for animals and humans.

A Leader In Precision Radionuclide Therapy™

How We Are Changing The Way Cancer Is Treated

Vivos Inc. - The  Leader In Precision Radionuclide Therapy™


Vivos Inc.'s strategic endeavors in medical and veterinary oncology are indeed pushing the boundaries of healthcare innovation. Holding nearly 30 patents including Precision Radionuclide Therapy™ and trademark protection for IsoPet®, RadioGel®, Alpha-Gel™, Beta-Gel™ and Gamma-Gel™ just to name a few, Vivos Inc. is securing its place as the leader in radionuclide therapy.  


Expansion into Veterinary Care with IsoPet®


Vivos Inc. has been expanding its reach in veterinary medicine with a Yttrium-90-based Precision Radionuclide Therapy™ for treatment used for solid tumors in animals. The equine healthcare market is experiencing significant growth, driven by rising demand in various sectors including racing and sports, along with increased awareness and investment in equine health. In 2023, the global equine healthcare market size was estimated at approximately $1.5 billion and is projected to reach $2.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 5.6%. North America is a dominant player in this market, largely because of a well-established equine industry.In terms of veterinary oncology, which includes cancer treatment for horses among other animals, the market was valued at $923.5 million in 2023 and is anticipated to grow to $1.7 billion by 2032. This growth is attributed to the increasing incidence of cancer among animals, advancements in cancer diagnostics and treatment, and a greater focus on pet health. 


Vivos Inc. has been focusing efforts to certify additional clinics to offer IsoPet® treatment, enhancing access to advanced cancer treatments for cats, dogs and horses. There is also an opportunity to treat exotic animals and the company is in discussion with several interested parties to open a broader market for IsoPet®. 


Clinical Trials with RadioGel®


Dr. Michael Korenko, CEO stated, “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel® is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel® for delivering therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease. The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.”


Vivos Inc.'s recent achievement of OTCQB certification is a significant development, underscoring the company's dedication to transparency and regulatory compliance. On March 22, 2024, CEO Dr. Michael Korenko led the company to secure its registration under Section 12(g) of the Exchange Act. This certification is more than procedural; it reflects Vivos Inc.'s strategic foresight and proactive approach in maintaining high governance standards, ultimately benefiting investors and partners by providing clear insights into the company's operations and financial health. 


Our team of experts brings together diverse backgrounds and skill sets, enabling us to tackle complex challenges and develop new products that have the potential to change lives. We are committed to making a positive impact on society, and we believe that biotechnology can be a powerful tool for addressing global challenges such as disease, food security, and environmental sustainability.


With critical FDA designations for its groundbreaking treatments and achieving milestones like OTCQB certification, Vivos Inc. is demonstrating its commitment to innovating the treatment of cancer and saving lives worldwide.  

Cancer Is On The Rise

At Vivos Inc. we are dedicated to revolutionizing the biotechnology industry. With a focus on innovation and scientific excellence, we are working to find new solutions to the way cancer is treated.


In 2023, it's estimated that around 43,720 recent cases of thyroid cancer will be diagnosed in the United States, with about 2,120 fatalities expected from the disease. Thyroid cancer is notably more prevalent among women than men and tends to be diagnosed at a younger age compared to most other adult cancers, with the average age of diagnosis at 51 years. 


The incidence of thyroid cancer has been increasing, which may in part be because of advancements in diagnostic technologies that can now detect smaller cancers that might not have been found in the past. It's important for ongoing research and patient support to adapt to these trends to optimize treatment strategies and improve outcomes. 


According to the latest data from the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases and 9.7 million cancer deaths globally in 2022. Lung and breast cancers are the most prevalent worldwide, with lung cancer also being the leading cause of cancer death overall and in men. For women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death. 


The projections suggest a surge to 35 million cancer cases by 2050, mainly because of population growth and aging, if current incidence rates remain unchanged. 

Meet The Team

Our Chairman

Chief Technical Manager

President & CEO

Carlton M. Cadwell


Dr. Carlton Cadwell leverages over 30 years of experience in the corporate world leading Cadwell Laboratories, a major international provider of neurodiagnostic devices. Dr. Carlton Cadwell brings a proven track record in business leadership and innovation.

President & CEO

Chief Technical Manager

President & CEO

Michael K. Korenko


Dr. Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense. Dr. Korenko currently is the author of 28 patents and possesses extensive experience in nuclear applications. Dr. Korenko is leading the Vivos Inc. team into treating cancer in animals and humans.

Chief Technical Manager

Chief Technical Manager

Chief Technical Manager

David Swanberg


Mr. David Swanberg has over 30 years experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management. He has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion dollar annual revenues.

Chief Financial Officer

Product Development Manager

Chief Technical Manager

Michael Pollack


Mr. Pollack is  Member of The American Institute of Certified Public Accountants and Partner at KBL LLP. Mr. Pollack received an undergraduate degree from the University of Maryland.

Product Development Manager

Product Development Manager

Product Development Manager

Dr. Jim Duncan


Dr. Duncan is a Doctor of Philosophy, holds a Master of Science in Immunochemistry, a Bachelor of Science in Bacteriology and Chemistry.  With more than 30 years experience and countless projects, publications and patents under his belt he has worked for the Department of Defense bringing concepts from the laboratory to production. Dr. Duncan oversees the production of more Peltier Chillers.

Quality Assurance Manager

Product Development Manager

Product Development Manager

Frederick Swindler


Mr. Swindler has a B.S. Biomedical Engineering, a M.B.A and is an ISO 9000 Auditor. With over 50 years in the industry Mr. Swindler offers Vivos extensive expertise in quality assurance and regulatory affairs in the medical device industry with specific emphasis in development and auditing of quality systems and product submissions.

Business Development Manager

Social Media & Marketing Advisor

Social Media & Marketing Advisor

Brad Weeks


Brad Weeks holds a Master of Business Administration (MBA) with a focus on Technology Management. He brings a unique blend of experience in service and support, regulatory affairs, quality management systems, and sales operations. Brad possesses diverse experience across the semiconductor and medical device industries. 

Social Media & Marketing Advisor

Social Media & Marketing Advisor

Social Media & Marketing Advisor

LeeAnna D. Binder


LeeAnna Binder has 25yrs experience in the corporate marketing field and holds certificates in graphic design. digital marketing, content creation and graphics communication. LeeAnna joined Vivos Inc. in 2024 while working towards her PhD in Natural Medicine specializing in innovative cancer treatment.

Vivos Inc. and Precision Radionuclide Therapy™

The Next Generation Breakthrough Cancer Treatment

Vivos Inc. (OTCQB: RDGL) is a medical device company on the forefront of changing the way cancer is treated with its patented Precision Radionuclide Therapy™.  Also known as PRnT™, the treatment uses a highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area and delivers therapeutic radiation from within the tumor. Vivos Inc. has developed an Yttrium-90 based injectable device to treat tumors in animals (IsoPet® Division) and humans (RadioGel® Division).

Radionuclide therapy, also known as nuclear medicine therapy or radiopharmaceutical therapy, involves the use of radioactive substances to treat diseases, most commonly cancer. The therapy utilizes radionuclides, which are radioactive isotopes, attached to molecules that can specifically target cancer cells. This allows the radionuclides to deliver targeted radiation directly to the tumor or diseased area, minimizing damage to surrounding healthy tissue.


In this treatment, the radioactive isotopes emit radiation that damages the DNA of the targeted cells, leading to cell death or a significant reduction in the cell's ability to multiply. The most familiar forms of radionuclide therapy include treatments for thyroid cancer using iodine-131, pain relief from bone metastases with strontium-89 or samarium-153, and peptide receptor radionuclide therapy (PRRT) for treating neuroendocrine tumors using radiolabeled peptides. Vivos Inc. and their patented Precision Radionuclide Therapy™ uses Yttrium-90 to kill tumors and is revolutionizing the treatment of cancer.


Yttrium-90’s Role In Cancer Treatment


Yttrium-90 (Y-90) is a radioactive isotope commonly used in radionuclide therapy, particularly for cancer treatment. Y-90 emits beta radiation, which is effective for treating certain types of cancers because of its ability to deliver high doses of radiation to localized areas with minimal impact on surrounding healthy tissue. Here are some key applications of Yttrium-90 in cancer therapy:


  • Radioembolization: Also known as selective internal radiation therapy (SIRT), it involves delivering Y-90 microspheres directly into the arteries feeding a tumor, typically in the liver. This is commonly used for treating hepatocellular carcinoma (primary liver cancer) and metastatic colorectal cancer in the liver when surgery is not an option.
  • Radiosynovectomy: Y-90 is used to treat inflammation in the synovial joints (such as in rheumatoid arthritis) by injecting it directly into the joint. Although not a cancer treatment, it's worth mentioning for its therapeutic use in joint disease using radiation.
  • Non-Hodgkin Lymphoma: Y-90 is conjugated to monoclonal antibodies that target specific cancer cells in some types of non-Hodgkin lymphoma. The antibodies deliver Y-90 directly to the cancer cells, where it can destroy them with localized radiation.


The use of Y-90 allows for high precision in targeting tumors, reducing the risk of side effects typically associated with external beam radiation. The treatment planning involves sophisticated imaging techniques to ensure accurate delivery of the radioactive material.


Y-90 therapy has been shown to be effective in extending survival and improving the quality of life for patients with specific types of cancer, making it a valuable option in the oncological toolkit.


Radionuclide therapy has several advantages, including its ability to treat cells systematically throughout the body, which makes it particularly useful for conditions where cancer cells have spread to multiple locations. It is typically considered for use when other treatments have failed or as an adjunct to other therapies to enhance their effectiveness.


The Radionuclide Market 


  • The market for radionuclide therapy is expected to experience steady growth in the coming years, driven by several factors:
  • Rising Cancer Burden: The increasing prevalence of cancer globally creates a larger patient pool for this treatment approach.
  • Targeted Therapy Advantages: Radionuclide therapy offers a targeted approach with potentially fewer side effects compared to traditional radiation therapy.
  • Technological Advancements: Developments in radiopharmaceuticals and targeted isotopes are improving the effectiveness and specificity of the treatment.
  • Focus on Minimally Invasive Procedures: Radionuclide therapy can sometimes be administered with minimal invasiveness, leading to faster recovery and potentially lower costs.
  • Market segments - The radionuclide therapy market can be segmented based on various factors, including:
  • Type of Radionuclide: Different isotopes with varying properties are used for specific applications.
  • Cancer Type: The market can be further segmented by the types of cancers treated with radionuclide therapy (e.g., prostate cancer, neuroendocrine tumors).
  • Delivery Method: The market can be segmented based on how the radiopharmaceuticals are administered (e.g., oral, intravenous, injection).
  • Market Research - While a single definitive market size for the global radionuclide therapy market might be elusive, some market research firms provide reports on related segments:
  • Radioligand Therapy Market: This segment focuses on radiopharmaceuticals that use antibodies or peptides to target cancer cells. 
  • Radionuclide Therapy Market: Considering the growth drivers and targeted therapy advantages, the radionuclide therapy market is expected to be a promising area within nuclear medicine.
  • Reports suggest this market could reach USD 13 billion by 2030


The global radiation therapy market size was estimated at $7.47 billion in 2023 and is expected to reach $10.4 billion to $16.3 billion by 2033 at a CAGR of 8.58% from 2024 to 2033. Major companies like Pfizer (NYSE: PFE) are returning to their emphasis on cancer treatment after focusing on COVID-19 for the past few years. Other major pharmaceutical companies like AstraZeneca(NASDAQ: AZN) and Eli Lilly (NYSE: LLY) are also going nuclear with radiation to tackle cancer, and Big Pharma’s billions of dollars in investments in nuclear medicine highlight how cancer treatment is shifting to targeted approaches.

Vivos Inc. has made significant developments in both their human and animal divisions. The company has achieved milestones announcing that the FDA granted RadioGel® Precision Radionuclide Therapy™ the designation of a Breakthrough Device and will use this designation to accelerate clinical trial approvals. The IsoPet® division is treating animal cancer in eight clinics across the United States and is expanding quickly. Key regional clinics are the University of Missouri, Johns Hopkins Medicine, and the most recently certified University of Wisconsin for Equine cancer treatment. The RadioGel® Division is working closely with the Mayo Clinic for the initial indication for delivering therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer. 


Expansion into Veterinary Care with IsoPet®


Vivos Inc. has been expanding its reach in veterinary medicine with a Yttrium-90 based Precision Radionuclide Therapy™ for treatment used for solid tumors in animals. The equine healthcare market is experiencing significant growth, driven by rising demand in various sectors including racing and sports, along with increased awareness and investment in equine health. In 2023, the global equine healthcare market size was estimated at approximately $1.5 billion and is projected to reach $2.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 5.6%. North America is a dominant player in this market, largely because of a well-established equine industry.


In terms of veterinary oncology, which includes cancer treatment for horses among other animals, the market was valued at $923.5 million in 2023 and is anticipated to grow to $1.7 billion by 2032. This growth is attributed to the increasing incidence of cancer among animals, advancements in cancer diagnostics and treatment, and a greater focus on pet health. 


Vivos Inc. has been focusing efforts to certify additional clinics to offer IsoPet® treatment, enhancing access to advanced cancer treatments for cats, dogs and horses. There is also an opportunity to treat exotic animals and the company is in discussion with several interested parties to open a broader market for IsoPet®. 


Clinical Trials with RadioGel®


Dr. Michael Korenko stated, “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel® is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel® for delivering therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease. The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.”


Cancer On The Rise


In 2023, it's estimated that around 43,720 recent cases of thyroid cancer will be diagnosed in the United States, with about 2,120 fatalities expected from the disease. Thyroid cancer is notably more prevalent among women than men and tends to be diagnosed at a younger age compared to most other adult cancers, with the average age of diagnosis at 51 years. The incidence of thyroid cancer has been increasing, which may in part be because of advancements in diagnostic technologies that can now detect smaller cancers that might not have been found in the past. It's important for ongoing research and patient support to adapt to these trends to optimize treatment strategies and improve outcomes. 


According to the latest data from the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases and 9.7 million cancer deaths globally in 2022. Lung and breast cancers are the most prevalent worldwide, with lung cancer also being the leading cause of cancer death overall and in men. For women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death. The projections suggest a surge to 35 million cancer cases by 2050, mainly because of population growth and aging, if current incidence rates remain unchanged. 


Vivos Inc. - The  Leader In Precision Radionuclide Therapy™


Vivos Inc.'s strategic endeavors in medical and veterinary oncology are indeed pushing the boundaries of healthcare innovation. Holding nearly 30 patents including Precision Radionuclide Therapy™ and trademark protection for IsoPet®, RadioGel®, Alpha-Gel™, Beta-Gel™ and Gamma-Gel™. Vivos Inc. is securing its place as the leader in radionuclide therapy. 


Vivos Inc.'s recent achievement of OTCQB certification is a significant development, underscoring the company's dedication to transparency and regulatory compliance. On March 22, 2024, CEO Dr. Michael Korenko led the company to secure its registration under Section 12(g) of the Exchange Act. This certification is more than procedural; it reflects Vivos Inc.'s strategic foresight and proactive approach in maintaining high governance standards, ultimately benefiting investors and partners by providing clear insights into the company's operations and financial health. 


With critical FDA designations for its groundbreaking treatments and achieving milestones like OTCQB certification, Vivos Inc. is demonstrating its commitment to innovating the treatment of cancer and saving lives worldwide. 


RadioGel® is currently not approved for human therapy.

Vivos Inc.

Vivos Inc. (OTCQB: RDGL)

Copyright © 2024 Vivos Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept